Summary
1KJ Chart
Torex Gold Resources Inc. (TXG) Closes the Market
Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Jody Kuzenko, President & Chief Executive Officer, Torex Gold Resources Inc. ("Torex" or the "Company") (TSX: TXG), and her team, joined Dean McPherson, Head, Business Development, Global Mining, Toronto Stock Exchange (TSX), to close the market and celebrate the Company's 15th anniversary of being listed on TSX. Cannot view this video?
Torex Gold Releases 2024 Responsible Gold Mining Report
Report shines a spotlight on continued leadership in responsible mining (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) today released its 2024 Responsible Gold Mining Report (the "Report") titled Building from Strength, the Company's tenth annual disclosure of its safety, environmental, social and governance performance. The Report can be found on the Company's website at www.torexgold.com.
Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
10x Genomics Inc. Dividends
10x Genomics Inc. Earnings
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 13 Feb 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 13 Feb 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
10x Genomics Inc. (1KJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 10x Genomics Inc. ever had a stock split?
10x Genomics Inc. Profile
| Medical - Healthcare Information Services Industry | Healthcare Sector | Dr. Serge Saxonov Ph.D. CEO | XDUS Exchange | US88025U1097 ISIN |
| US Country | 1,306 Employees | - Last Dividend | - Last Split | 12 Sep 2019 IPO Date |
Overview
10x Genomics, Inc. is a prominent life science technology company known for its innovative development and commercialization of instruments, consumables, and software aimed at analyzing biological systems. The company's footprint extends across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific regions, catering to a diverse clientele that includes academic, government, biopharmaceutical, biotechnology, and other institutions. Originally named 10X Technologies, Inc., it underwent a rebranding to 10x Genomics, Inc. in November 2014. Since its inception in 2012, 10x Genomics has established its headquarters in Pleasanton, California, positioning itself as a leader in the field of genomics and cellular analysis.
Products and Services
- Chromium Instruments: This product line includes the chromium, chromium connect, and chromium controller instruments. These are cornerstone tools for 10x Genomics, facilitating a range of single cell solutions that enable researchers to delve into the intricacies of gene activity and networks on a cell-by-cell basis. The chromium instruments are complemented by microfluidic chips, slides, reagents, and other essential consumables.
- Single Cell Solutions:
- Single Cell Gene Expression: This solution measures gene activity and networks at the individual cell level, providing detailed insights into cellular functions.
- Single Cell Immune Profiling: Targeted at studying the immune system, this solution offers a detailed look at immune cell interactions and functions.
- Single Cell Assay for Transposase Accessible Chromatin (ATAC): Designed to explore the epigenetic landscape of cells, this solution unveils how the accessibility of chromatin influences gene expression.
- Single Cell Multiome ATAC + Gene Expression: This solution allows for the simultaneous investigation of RNA and chromatin accessibility within a single cell, presenting a comprehensive view of cellular function.
- Visium Platform: The Visium platform represents a revolutionary step in tissue analysis, providing researchers with the ability to understand the spatial positioning of biological analytes within tissues at high resolutions. This is crucial for comprehending the complex interplay between cellular components in various biological and pathological states.
- Xenium Platform: Geared towards in situ analysis, the Xenium platform offers an innovative method for analyzing molecular and cellular biology directly within tissue samples. This approach is pivotal for advancing our understanding of complex biological systems and diseases.
Contact Information
